# Nxera Pharma Posts $175 Million Q3 Revenue as Ten R&D Milestones Lift Results > Nxera Pharma reported Q3 2026 revenue of $175 million, driven by ten R&D milestones, and exercised its option to license lucerastat from Idorsia. - Published: 2026-10-30T06:50:35+00:00 - Section: Earnings & Results - Author: News Desk - URL: https://newsforagent.com/news/2026-10-30/nxera-pharma-q3-2026-revenue-milestones - Source: [GlobeNewswire](https://www.globenewswire.com/news-release/2026/10/30/3392032/0/en/nxera-pharma-operational-highlights-and-consolidated-results-for-the-third-quarter-2026.html) ## Key takeaways - Nxera Pharma reported Q3 2026 revenue of JPY 27,742 million (US$175 million), up JPY 5,894 million from the prior period. - Nxera received a US$10 million milestone from Neurocrine and a US$8.6 million milestone from Centessa during the quarter. - Nxera exercised its option to in-license lucerastat from Idorsia, paying CHF 7 million upfront for rights in Japan, South Korea, Taiwan and selected Asia-Pacific markets. [Nxera Pharma](https://akta.pro/company-profiles/000418w/nxera-pharma) reported third-quarter 2026 revenue of JPY 27,742 million (US$175 million), an increase of JPY 5,894 million from the prior corresponding period, driven by ten R&D milestones. The company said in its [GlobeNewswire](https://www.globenewswire.com/news-release/2026/10/30/3392032/0/en/nxera-pharma-operational-highlights-and-consolidated-results-for-the-third-quarter-2026.html) results release that the milestone count compared with six in the prior period. ## Nxera's Milestones and Lucerastat Option Nxera Pharma is a Tokyo-headquartered biopharmaceutical company that uses its NxWave GPCR structure-based drug discovery platform to develop therapeutics and commercializes PIVLAZ and QUVIVIQ in Japan and the Asia-Pacific region, according to company records. Chris Cargill, President and CEO of Nxera, said: "These achievements demonstrate that our drug discovery, development and partnering strategy is delivering tangible results and strengthening the foundation for future growth." Under its collaboration with Neurocrine Biosciences, Nxera achieved a US$10 million milestone following progress in the development of NBI-1117567, an M1 receptor agonist for cognitive impairment associated with Alzheimer's disease. A further US$8.6 million milestone was achieved following late-stage development progress in the orexin receptor 2 agonist program originating from its collaboration with Centessa Pharmaceuticals, which was acquired by Eli Lilly and Company. Since the end of the third quarter, Nxera exercised its option to in-license lucerastat, a treatment candidate for Fabry disease, from [Idorsia](https://akta.pro/company-profiles/00009sm/idorsia) and entered a co-development and commercialization agreement. Nxera will pay Idorsia an upfront payment of CHF 7 million and holds exclusive rights in Japan, South Korea, Taiwan and selected other Asia-Pacific markets, excluding China. Idorsia announced a proposed SPV partnership to fund TRYVIO/JERAYGO commercialization with CHF 120 million, split between noteholders and the company, according to TradingView. ## Nxera's Financial Results for the Nine Months According to akta.pro [company records](https://akta.pro/company-data), Nxera's FY2025 total revenue was JPY 29.6 billion (about US$197.9 million), up from JPY 28.8 billion year-on-year. PIVLAZ commercial revenue was JPY 13,511 million (US$90.3 million), up 6.8% year-on-year, while QUVIVIQ commercial revenue was JPY 4,327 million (US$28.9 million), up 223.9% year-on-year. For the nine months ended September 30, 2026, Nxera reported operating profit of JPY 3,175 million (US$20.0 million), compared with an operating loss of JPY 5,907 million in the prior corresponding period. Net profit was JPY 2,328 million (US$14.7 million), versus a net loss of JPY 4,809 million a year earlier. Cash and cash equivalents stood at JPY 16,613 million (US$105.6 million) as of September 30, 2026. ## Nxera's Path to the Third Quarter In August 2026, Nxera reported first-half GAAP earnings per share of ¥15.86 and revenue of ¥18.91 billion, a 25.3% year-over-year increase, according to Seeking Alpha. That month, Neurocrine Biosciences received FDA IND acceptance for a Phase 2 study of NBI-1117567 for Alzheimer's cognition, Yahoo reported. In June 2026, Nxera said it would receive a US$10 million milestone payment from [AbbVie](https://akta.pro/company-profiles/00000r2/abbvie) under their collaboration targeting neurological diseases, according to GlobeNewswire. ## Nxera's Regulatory Targets in South Korea Nxera is targeting regulatory approval in South Korea for vamorolone in 2027 and commercial launch in 2028. The global Phase 3 development program for lucerastat is expected to support a regulatory filing as early as 2029. ## Companies in this story - [Nxera Pharma company profile](https://akta.pro/company-profiles/000418w/nxera-pharma) · website: https://www.nxera.life - [Idorsia company profile](https://akta.pro/company-profiles/00009sm/idorsia) · website: https://www.idorsia.com - [AbbVie company profile](https://akta.pro/company-profiles/00000r2/abbvie) · website: https://www.abbvie.com --- News for Agent · https://newsforagent.com/llms.txt